Post by Admin on Feb 27, 2021 18:01:58 GMT
Call to Monitor Adverse Effects of Antipsychotics in Youth
Researchers point to the risks of using antipsychotics with youth and caution against the practice.
www.madinamerica.com/2018/08/call-to-monitor-adverse-effects-of-antipsychotics-in-youth/
A recent editorial published in JAMA Psychiatry responds to a randomized controlled trial (RCT) examining the metabolic effects of second-generation antipsychotics (SGA) in young people. In the RCT, the researchers monitored the metabolic effects of antipsychotics (aripiprazole, olanzapine, and risperidone) in a group of nonpsychotic youth diagnosed with behavioral disorders. The results showed adverse metabolic effects across the 12 weeks with the most significant effects found for the antipsychotic olanzapine. The researchers associated these adverse effects on premature cardiometabolic morbidity and mortality.
“The potential psychiatric benefits of antipsychotic use in this population, evident in this trial and others, should be carefully weighed against the potential for childhood onset of abdominal obesity and insulin resistance that—compared with adult onset—further increases long-term risk for T2D, cardiovascular disease, and related conditions,” the researchers write.
Editorial
August 2018
The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication
Marc De Hert, MD, PhD1,2; Johan Detraux, MPsy2
Author Affiliations
JAMA Psychiatry. 2018;75(8):771-772. doi:10.1001/jamapsychiatry.2018.1080
jamanetwork.com/journals/jamapsychiatry/article-abstract/2683877
Over the last 2 decades, there has been increasing widespread use of second-generation antipsychotic (SGA) medications in nonpsychotic pediatric populations in the United States and Europe.1-3 As the ubiquity of SGA drugs in treatment plans for these children and adolescents grows, so does the controversy surrounding them.
Full Text
Researchers point to the risks of using antipsychotics with youth and caution against the practice.
www.madinamerica.com/2018/08/call-to-monitor-adverse-effects-of-antipsychotics-in-youth/
A recent editorial published in JAMA Psychiatry responds to a randomized controlled trial (RCT) examining the metabolic effects of second-generation antipsychotics (SGA) in young people. In the RCT, the researchers monitored the metabolic effects of antipsychotics (aripiprazole, olanzapine, and risperidone) in a group of nonpsychotic youth diagnosed with behavioral disorders. The results showed adverse metabolic effects across the 12 weeks with the most significant effects found for the antipsychotic olanzapine. The researchers associated these adverse effects on premature cardiometabolic morbidity and mortality.
“The potential psychiatric benefits of antipsychotic use in this population, evident in this trial and others, should be carefully weighed against the potential for childhood onset of abdominal obesity and insulin resistance that—compared with adult onset—further increases long-term risk for T2D, cardiovascular disease, and related conditions,” the researchers write.
Editorial
August 2018
The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication
Marc De Hert, MD, PhD1,2; Johan Detraux, MPsy2
Author Affiliations
JAMA Psychiatry. 2018;75(8):771-772. doi:10.1001/jamapsychiatry.2018.1080
jamanetwork.com/journals/jamapsychiatry/article-abstract/2683877
Over the last 2 decades, there has been increasing widespread use of second-generation antipsychotic (SGA) medications in nonpsychotic pediatric populations in the United States and Europe.1-3 As the ubiquity of SGA drugs in treatment plans for these children and adolescents grows, so does the controversy surrounding them.
Full Text